Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States & European Union — European Medicines Agency

35 shared events · Importance 4 · Last updated Sep 24, 2026

Importance
4
Shared Events
35
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
52
Regulatory
United States: Jurisdiction where hundreds of patients have sued the GLP-1 drugmakers and where the United States — Food and Drug Administration has so far declined to add a NAION warning label, unlike regulators abroad.
European Union — European Medicines Agency: Estimated NAION could affect up to one in 10,000 people with diabetes using GLP-1 medicines and required updated warnings on semaglutide product information in 2025. Its action sets a precedent that US regulators have not followed.
Sep 21, 2026 · 20 articles
49
Tech
United States: The United States is one of the countries where hantavirus patients are being treated.
European Union — European Medicines Agency: The European Union — European Medicines Agency identified favipiravir as the most plausible candidate for hantavirus treatment under clinical trial or compassionate use protocols.
May 28, 2026 · 6 articles
49
Regulatory
United States: The U.S. is a key market for the vaccine, with high Lyme disease incidence and a large at-risk population.
European Union — European Medicines Agency: The EMA is the regulatory body validating and assessing the application. Its decision will determine market access in Europe.
Aug 14, 2026 · 12 articles
45
Regulatory
United States: The U.S. is the primary market for the regulatory submission.
European Union — European Medicines Agency: The EMA is also reviewing the combination for the same indication.
Jul 22, 2026 · 6 articles
44
Regulatory
United States: The United States is the primary market for the filing, with the FDA review and potential launch driving the commercial significance of the event.
European Union — European Medicines Agency: The EMA validated Roche's application for Enspryng in MOGAD in Europe, advancing the parallel European regulatory pathway.
Sep 09, 2026 · 6 articles
39
Business
United States: The United States is a key market for the potential launch of zeleciment basivarsen, with Dyne Therapeutics targeting U.S. Accelerated Approval and a U.S. launch in H1 2028.
European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) has granted Orphan Drug designation to zeleciment basivarsen, indicating Dyne Therapeutics' pursuit of approval pathways outside of the U.S.
Jun 03, 2026 · 6 articles
39
Regulatory
United States: The United States, through the FDA, granted the key approval, making it the primary market for Moderna's updated vaccines.
European Union — European Medicines Agency: The European Union — European Medicines Agency approved the Spikevax formula, expanding Moderna's market access in Europe.
Aug 27, 2026 · 6 articles
39
Regulatory
United States: Target market for Zealand Pharma's planned US New Drug Application, supported by the ongoing Phase 3 EASE-5 trial.
European Union — European Medicines Agency: Its CHMP committee issued the positive opinion that drives the event, reinforcing the agency's role as the gatekeeper for EU drug approvals.
Sep 18, 2026 · 6 articles
35
Business
United States: The US is a key market for PentixaFor, with an expanded patient pool due to new screening guidelines.
European Union — European Medicines Agency: The EMA granted PRIME status to PentixaFor, providing enhanced support for its development and approval in European Union — Europe.
Jul 15, 2026 · 10 articles
32
Regulatory
United States: The United States>>> is the market where the United States — Food and Drug Administration>>> accepted the BLA for AVT16, potentially expanding biosimilar options for patients and healthcare providers.
European Union — European Medicines Agency: The European Union — European Medicines Agency>>> has validated a Marketing Authorization Application for AVT16 and AVT80, indicating progress in European markets.
Jun 08, 2026 · 11 articles
30
Regulatory
United States: The United States is a target for a Biologics License Application (BLA) submission in early 2027 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the country.
European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) is mentioned as a target for a Marketing Authorization Application (MAA) in 2026 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the European Union.
Jun 25, 2026 · 6 articles
30
Regulatory
United States: Trixeo is already approved there as Breztri Aerosphere for asthma and COPD, providing the commercial precedent for the EU expansion.
European Union — European Medicines Agency: Its scientific assessment underpinned the approval, with the positive CHMP opinion paving the way for the International — European Commission decision.
Sep 23, 2026 · 10 articles
28
Regulatory
United States: Country where trofinetide is approved under the name DAYBUE, providing a reference for the EU approval.
European Union — European Medicines Agency: The EMA's advisory committee recommended approval, which preceded the International — European Commission's decision.
Aug 24, 2026 · 7 articles
27
Business
United States: The US is a key market for YUVIWEL, with rapid uptake noted; the settlement secures Ascendis' ability to sell there.
European Union — European Medicines Agency: The EMA is reviewing Ascendis' marketing application for YUVIWEL, with a decision expected in Q4 2026, which could expand the market.
Aug 31, 2026 · 6 articles
24
Business
United States: The United States is highlighted as the largest pharmaceutical market globally, making it a key focus for EirGenix's expansion and partnership discussions.
European Union — European Medicines Agency: The European Union — European Medicines Agency is mentioned as a regulatory agency whose harmonized frameworks are streamlining biosimilar approval pathways, benefiting companies like EirGenix.
Jun 30, 2026 · 6 articles
24
Domestic
United States: The US has shifted toward a risk-based approach; Health Secretary Robert F. Kennedy Jr. has advocated stopping recommendations for children.
European Union — European Medicines Agency: EMA oversees vaccine safety in the EU and received confidential documents from BioNTech regarding adverse events, but the policy change is a national decision.
Jul 13, 2026 · 6 articles
24
Regulatory
United States: Jurisdiction where the FDA and courts are located; regulatory decisions affect patient access and market dynamics.
European Union — European Medicines Agency: Granted orphan drug designation; not directly involved in the FDA setback.
Jul 27, 2026 · 305 articles
24
Business
United States: The US represents a significant potential market for Idefirix, with FDA review ongoing and a decision expected in December 2026.
European Union — European Medicines Agency: The EMA's prior conditional approval and PRIME designation support Idefirix's regulatory standing in Europe, though not directly impacted by this event.
Aug 18, 2026 · 6 articles
24
Regulatory
United States: The United States, through the FDA, approved the drug, making it available to American patients and potentially influencing global regulatory decisions.
European Union — European Medicines Agency: The EMA is conducting a rolling review of daraxonrasib, which could lead to a marketing authorization application in Europe, expanding the drug's global reach.
Aug 26, 2026 · 92 articles
24
Business
United States: The United States is one of the countries where Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel has been evaluated in clinical trials and where additional regulatory filings are planned.
European Union — European Medicines Agency: The European Union — European Medicines Agency has granted orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification, and priority medicines (PRIME) designation to Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel.
Jun 10, 2026 · 6 articles
24
Business
United States: Regulatory jurisdiction where FDA designations were granted and where commercialization rights are included.
European Union — European Medicines Agency: Granted PRIME designation for lacutamab in Sézary syndrome, supporting accelerated assessment.
Aug 10, 2026 · 10 articles
24
Regulatory
United States: The US approved Skyclarys in February 2023, establishing its clinical use and market availability. This early approval informed global access discussions, including in Republic of Ireland.
European Union — European Medicines Agency: The EMA approved Skyclarys in 2024, providing the regulatory basis for its use in Europe, which facilitated national reimbursement decisions.
Aug 14, 2026 · 23 articles
14
Business
United States: Country where Palsonify is approved and where most patients reside.
European Union — European Medicines Agency: Approved Palsonify for acromegaly in the EU.
Jul 06, 2026 · 34 articles
7
Business
United States: The United States is mentioned in the context of Oman's last bilateral agreement in 2006, providing historical context for Oman's trade policy.
European Union — European Medicines Agency: Indian generic medicines approved by the European Union — European Medicines Agency>>> will receive fast-track marketing authorization in Oman>>> under the CEPA.
May 29, 2026 · 79 articles
7
Business
United States: Ascentage Pharma has a U.S. presence and FDA clearances, but this event does not directly impact the country.
European Union — European Medicines Agency: The EMA has cleared several of Ascentage Pharma's Phase III trials, but this event does not directly involve the EMA.
Jul 26, 2026 · 6 articles
5
Business
United States: Cosmos Health is expanding in the US; the buyback is a corporate action with no direct impact on the country.
European Union — European Medicines Agency: The EMA certifies Cana Laboratories; the buyback has no direct impact on this relationship.
Jun 30, 2026 · 63 articles
0
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent for chronic spontaneous urticaria (CSU) in the European Union.
Feb 24, 2026 · 8 articles
0
Tech
Jan 16, 2026 · 23 articles
0
Business
Apr 14, 2026 · 6 articles
0
Business
Apr 13, 2026 · 8 articles
+ 5 more events View on Dashboard
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States and European Union — European Medicines Agency interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.